Read by QxMD icon Read

Vaccination against HPV

Carmen Radecki Breitkopf, Lila J Finney Rutten, Victoria Findley, Debra J Jacobson, Patrick M Wilson, Monica Albertie, Robert M Jacobson, Gerardo Colón-Otero
Human papillomavirus (HPV) vaccines offer primary prevention of cervical cancer and protection against other HPV-associated cancers. HPV vaccine coverage in the United States (U.S.) remains low, particularly among older adolescents/young adults, and the uninsured. We assessed awareness and knowledge of HPV disease, HPV-related cancers, and HPV vaccines among working, uninsured adults. Data from the 2014 Health Information National Trends Survey (HINTS 4, Cycle 4) were used as a benchmark. Patients were surveyed in late 2014 at the Volunteers in Medicine free clinic in Duval County, Florida...
October 17, 2016: Cancer Medicine
Ting Zhang, Hongyang Liu, Xue Chen, Zhirong Wang, Shuo Wang, Chunfeng Qu, Jingzhi Zhang, Xuemei Xu
Numerous types of human papillomaviruses (HPVs) have been identified, and the global burden of diseases associated with HPV infection is remarkable, especially in developing regions. Thus a low-cost broad-spectrum prophylactic vaccine is urgently needed. The N-terminal amino acid 17-36 of HPV 16 L2 protein is confirmed to be a major cross-neutralizing epitope (RG-1 epitope). Monomeric proteins containing RG-1 epitopes and scaffold proteins, such as bacterial thioredoxin or modified IgG1 Fc fragment and L2 epitope fusion protein, induced cross-neutralizing antibodies, arousing the possibility of the development of low-cost monomeric vaccine in bacterial expression system...
October 8, 2016: Vaccine
Zuyi Chen, Yaling Jing, Qiang Wen, Xianping Ding, Shun Zhang, Tao Wang, Yiwen Zhang, Jianhui Zhang
BACKGROUND: Cervical cancer is associated with infection by certain subtypes of human papillomavirus (HPV). The L1 protein comprising HPV vaccine formulations elicits high-titre neutralizing antibodies and confers protection against specific HPV subtypes. HPV L2 protein is an attractive candidate for cross-protective vaccines. HPV-33 and HPV-58 are very prevalent among Chinese women. METHODS: To study the gene intratypic variations and polymorphisms of HPV-33 and HPV-58 L1/L2 in Sichuan China, HPV-33 and HPV-58 L1 and L2 genes were sequenced and compared with other genes submitted to GenBank...
October 7, 2016: Virology Journal
Stina Syrjänen, Jaana Rautava
HPV-associated head and neck squamous cell carcinoma (HNSCC), more specifically the incidence of oropharyngeal cancer, is dramatically increasing in industrialized countries. According to what has been learned from anogenital vaccination programs, there are reasons to believe that current human papillomavirus (HPV) vaccinations may be potentially effective also against HNSCC. However, before specific results on HNSCC are available, one must keep in mind that carcinogenesis in the head and neck region may differ from that of the anogenital tract...
2017: Recent Results in Cancer Research
Soheila Moeini, Mohsen Saeidi, Fatemeh Fotouhi, Mahdieh Mondanizdeh, Sadegh Shirian, Alireza Mohebi, Ali Gorji, Amir Ghaemi
The use of DNA vaccines has become an attractive approach for generating antigen-specific cytotoxic CD8(+) T lymphocytes (CTLs), which can mediate protective antitumor immunity. The potency of DNA vaccines encoding weakly immunogenic tumor-associated antigens (TAAs) can be improved by using an adjuvant injected together with checkpoint antibodies. In the current study, we evaluated whether the therapeutic effects of a DNA vaccine encoding human papilloma virus type 16 (HPV-16) E7 can be enhanced by combined application of an immune checkpoint blockade directed against the programmed death-1 (PD-1) pathway and secondary lymphoid tissue chemokine (SLC) also known as CCL21 adjuvant, in a mouse cervical cancer model...
October 3, 2016: Archives of Virology
Ana Raposo, Chiara Tani, José Costa, Marta Mosca
An association between immune-mediated diseases and cervical pre-malignant and malignant lesions is described, having the human papillomavirus (HPV) infection a causal role. Related studies have been generally focused on systemic lupus erythematosus (SLE) patients, but relatively to other diseases, such as rheumatoid arthritis (RA), Sjögren's syndrome (SS) and systemic sclerosis (SSc), data has not been systematically evaluated. We conducted a systematic review analysis of the literature in PubMed, including articles published until March of 2015, in patients with RA, SS, SLE and SSc, to evaluate the frequency of HPV infection, cervical dysplasia and cervical cancer, and associated factors, with particular interest on the role of glucocorticoids and immunosuppressive treatment...
April 16, 2016: Acta Reumatológica Portuguesa
Laurent Abramowitz, Philippe Descamps, François Denis, Marie-Aliette Dommergues, Pierre Pradat, Jean Lacau St Guily, Philippe Judlin
BACKGROUND: In 2006, the HPV (Human papillomavirus) 6/11/16/18 quadrivalent vaccine was approved by the European Medicines Agency and obtained its marketing authorization in both girls and boys. Currently, the French guidelines recommend and refund vaccination of girls aged 11 to 14 with a catch-up program for females from 15 to 19 years old. DISCUSSION: In France, HPV vaccination coverage tends to decrease. At the end of 2015, the vaccination coverage with three doses reached only 14% in 16-year-old girls (three doses)...
September 27, 2016: Journal of Public Health
Kristin Keglovitz, Andrew D Richardson, Nicola Lancki, Tim Walsh, John A Schneider
PURPOSE: Limited data are available on anal squamous intraepithelial lesions (ASILs) and anal human papillomavirus (HPV) infection in young, black populations. The purpose of this study was to examine the prevalence of and relationships between ASILs and high-risk HPV infection in a young (<30 years of age), predominately black, men who have sex with men (MSM) population. METHODS: Results of anal cytology and HPV DNA were gathered for 83 individuals. RESULTS: Forty-two percent of individuals (35) had atypical squamous cells of undetermined significance and 33% (27) had low-grade intraepithelial lesion by cytology...
September 27, 2016: LGBT Health
Septimiu Voidăzan, Silviu-Horia Morariu, Monica Tarcea, Horatiu Moldovan, Ioana Curticăpian, Minodora Dobreanu
Human papillomavirus (HPV) infection, a causative factor for cervical cancer, remains a topic of great interest. About 80% of sexually active women are at risk of acquiring an HPV infection at some point in life, the peak incidence of infection having been identified in young women. The aim of the study was to assess the knowledge and attitudes of medical students about sexually transmitted diseases, HPV infection, HPV vaccinations, and student sexual behavior. A transversal study was conducted using a questionnaire on students on the 1st and 6th year at the Faculty of Medicine of Tîrgu Mureş University, Romania...
August 2016: Acta Dermatovenerologica Croatica: ADC
J Chanal, S Fouéré, F Yassir-Oria, N Spenatto, F Bouscarat, E Picot, P Martinet, C Vernay-Vaisse, F Pelletier, C Courtieu, V Baclet, C Bernier, D Aymar-Moulene, F Dupuis-Fourdan, A Passeron, C Bara-Passot, A-L Pinault, L Misery, M Janier, N Dupin
BACKGROUND: Since 2007 in France, human papilloma virus (HPV) vaccination has been licensed for use as a vaccine against HPV 6, 11, 16 and 18. The impact on the epidemiology of external genital warts (EGWs) in a large population remains unclear. OBJECTIVES: To determine epidemiologic and clinical features of patients presenting EGWs in France in the era of HPV vaccination. PATIENTS AND METHODS: In this prospective, observational study, we analyzed clinical features and treatments between January 1st, 2012 and March 31, 2012 for patients consulting for EGWs at 15 STI clinics throughout France...
September 19, 2016: Annales de Dermatologie et de Vénéréologie
David Mesher, Kate Soldan, Matti Lehtinen, Simon Beddows, Marc Brisson, Julia M L Brotherton, Eric P F Chow, Teresa Cummings, Mélanie Drolet, Christopher K Fairley, Suzanne M Garland, Jessica A Kahn, Kimberley Kavanagh, Lauri Markowitz, Kevin G Pollock, Anna Söderlund-Strand, Pam Sonnenberg, Sepehr N Tabrizi, Clare Tanton, Elizabeth Unger, Sara L Thomas
We analyzed human papillomavirus (HPV) prevalences during prevaccination and postvaccination periods to consider possible changes in nonvaccine HPV genotypes after introduction of vaccines that confer protection against 2 high-risk types, HPV16 and HPV18. Our meta-analysis included 9 studies with data for 13,886 girls and women ≤19 years of age and 23,340 women 20-24 years of age. We found evidence of cross-protection for HPV31 among the younger age group after vaccine introduction but little evidence for reductions of HPV33 and HPV45...
October 2016: Emerging Infectious Diseases
Stefanie Schülein, Katherine J Taylor, Jochem König, Matthias Claus, Maria Blettner, Stefanie J Klug
BACKGROUND: Adequate coverage is key to the success of human papillomavirus (HPV) vaccination programmes. There is currently no organised HPV vaccination programme in Germany. The aim of this analysis was to determine HPV vaccine uptake as well as factors associated with uptake in nine to 17 year-old girls in Germany during the first year of vaccine availability. METHODS: This analysis is based on data from the Healthcare Access Panel, an established population-based household panel consisting of 55 000 representative households in Germany who were contacted between September and October 2007...
2016: BMC Public Health
K Jeyachelvi, S Juwita, D Norwati
BACKGROUND: Cervical cancer though preventable is still the leading cause of cancer death among women secondary to breast cancer. Persistent infection with HPV has been causally linked to the disease. A school based HPV vaccination program was introduced in late 2010 in Malaysia and nurse support is essential for its success. OBJECTIVES: To determine nurses knowledge and attitudes about HPV infection and its vaccines, and factors associated with their knowledge...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Sharmila Chatterjee, Amit Chattopadhyay, Luna Samanta, Pinaki Panigrahi
Cervical cancer (CaCx) is the second most fatal cancer contributing to 14% of cancers in Indian females, which account for 25.4% and 26.5% of the global burden of CaCx prevalence and mortality, respectively. Persistent infection with high-risk human papilloma virus (HPV- strains 16 and 18) is the most important risk factor for precursors of invasive CaCx. Comprehensive prevention strategies for CaCx should include screening and HPV vaccination. Three screening modalities for CaCx are cytology, visual inspection with acetic acid, and HPV testing...
2016: Asian Pacific Journal of Cancer Prevention: APJCP
Jordan Mills, Patrick Van Winkle, Macy Shen, Christina Hong, Sharon Hudson
CONTEXT: Vaccination against the human papillomavirus (HPV) decreases risks of cancer and genital warts and the need for gynecologic procedures, yet nationwide vaccination rates are low. Previous surveys exploring this phenomenon have not included inputfrom nurses and medical assistants, who play integral roles in HPV vaccine delivery. OBJECTIVE: To understand perceptions of HPV vaccine delivery among physicians, nurses, and medical assistants in a large integrated health care system in Southern California...
September 14, 2016: Permanente Journal
Akiva P Novetsky, Marla J Keller, Ana Gradissimo, Zigui Chen, Stephanie L Morgan, Xiaonan Xue, Howard D Strickler, José A Fernández-Romero, Robert Burk, Mark H Einstein
OBJECTIVE: To assess in vitro efficacy of Divine 9, a carrageenan-based vaginal lubricant that is being studied as a microbicide to inhibit HPV16 pseudovirus (PsV) infection. METHODS: Sexually active US women between 19 and 35years without prior HPV vaccination or cervical intraepithelial neoplasia were instructed to use Divine 9 vaginally with an applicator either before sex only or before and after intercourse. Women who applied a single dose of gel returned for cervicovaginal lavage (CVL) collection 1, 4 or 8-12h after intercourse versus those who applied gel before and after intercourse returned 1, 4 or 8-12h after the second gel dose...
September 10, 2016: Gynecologic Oncology
Angelica M Roncancio, Kristy K Ward, Chakema C Carmack, Becky T Muñoz, Miguel A Cano, Felicity Cribbs
HPV vaccine series completion rates among adolescent Hispanic females and males (~39 and 21 %, respectively) are far below the Healthy People 80 % coverage goal. Completion of the 3-dose vaccine series is critical to reducing the incidence of HPV-associated cancers. This formative study applies social marketing theory to assess the needs and preferences of Hispanic mothers in order to guide the development of interventions to increase HPV vaccine completion. We conducted 51 in-depth interviews with Hispanic mothers of adolescents to identify the key concepts of social marketing theory (i...
September 13, 2016: Journal of Community Health
Rodney Macedo, Juliette Rochefort, Maude Guillot-Delost, Kae Tanaka, Aline Le Moignic, Clara Noizat, Claude Baillou, Véronique Mateo, Antoine F Carpentier, Eric Tartour, Chloé Bertolus, Bertrand Bellier, Géraldine Lescaille, François M Lemoine
Despite current therapy, head and neck squamous cell carcinomas (HNSCCs) arising from various mucosal sites of the upper aero-digestive tract frequently relapse in a loco-regional manner and have a poor prognosis. Our objective was to validate an innovative mucosal route of vaccination using plasmo virus-like particles (pVLPs) in a pre-clinical orthotopic model of HNSCCs. For this purpose, we used pVLP-E7, that are plasmid DNA encoding retroviral virus-like particles carrying a truncated E7 oncoprotein from HPV-16 as antigen model, to vaccinate mice bearing pre-established TC-1 tumors implanted into the buccal mucosa...
July 2016: Oncoimmunology
Peter Hillemanns, Phillip Soergel, Hermann Hertel, Matthias Jentschke
The new German S3 guideline 'Prevention of Cervical Cancer' published in 2016 is based on the latest available evidence about cervical cancer screening and treatment of cervical precancer. Large randomized controlled trials indicate that human papillomavirus (HPV)-based screening may provide better protection against cervical cancer than cytology alone through improved detection of premalignant disease in the first screening round prior to progression. Therefore, women aged 30 years and older should preferably be screened with HPV testing every 3-5 years (cytology alone every 2 years is an acceptable alternative)...
2016: Oncology Research and Treatment
Laura Ortega-Cervantes, Adriana Aguilar-Lemarroy, Aurora Elizabeth Rojas-García, Briscia Socorro Barrón-Vivanco, Verónica Vallejo-Ruiz, David Cantú-De León, Yael Yvette Bernal Hernández, Armando Jáuregui-Martínez, Irma Martha Medina-Díaz
OBJECTIVE: In Mexico cervical cancer (CC) is the most common cause of death from neoplasia in women. Study aimed to analyze the current distribution of Human papillomavirus (HPV) types in women from Nayarit, Mexico, with Squamous intraepithelial lesions (SIL) and Cervical cancer (CC). METHODOLOGY: Between January 2011 and July 2013, cervical samples were collected from female residents of the Mexican state of Nayarit and were analyzed by means of a LINEAR ARRAY® HPV genotyping test...
July 2016: International Journal of Health Sciences
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"